The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design - PubMed (original) (raw)
Review
doi: 10.1038/nri1901.
Affiliations
- PMID: 16868550
- DOI: 10.1038/nri1901
Review
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Thomas A Waldmann. Nat Rev Immunol. 2006 Aug.
Abstract
Interleukin-2 and interleukin-15 have pivotal roles in the control of the life and death of lymphocytes. Although their heterotrimeric receptors have two receptor subunits in common, these two cytokines have contrasting roles in adaptive immune responses. The unique role of interleukin-2 is in the elimination of self-reactive T cells to prevent autoimmunity. By contrast, interleukin-15 is dedicated to the prolonged maintenance of memory T-cell responses to invading pathogens. As discussed in this Review, the biology of these cytokines will affect the development of novel therapies for malignancy and autoimmune diseases, as well as the design of vaccines against infectious diseases.
Similar articles
- Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.
Waldmann TA, Dubois S, Tagaya Y. Waldmann TA, et al. Immunity. 2001 Feb;14(2):105-10. Immunity. 2001. PMID: 11239443 Review. No abstract available. - [Biology and immunotherapy advance of interleukin 2 and interleukin 15-review].
Chen GH, Wu DP. Chen GH, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Aug;17(4):1088-92. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009. PMID: 19698267 Review. Chinese. - The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy.
Waldmann TA. Waldmann TA. Cancer Immunol Res. 2015 Mar;3(3):219-27. doi: 10.1158/2326-6066.CIR-15-0009. Cancer Immunol Res. 2015. PMID: 25736261 Free PMC article. Review. - IL-15 in the life and death of lymphocytes: immunotherapeutic implications.
Waldmann TA. Waldmann TA. Trends Mol Med. 2003 Dec;9(12):517-21. doi: 10.1016/j.molmed.2003.10.005. Trends Mol Med. 2003. PMID: 14659465 Review. No abstract available. - The IL-2/IL-15 receptor systems: targets for immunotherapy.
Waldmann TA. Waldmann TA. J Clin Immunol. 2002 Mar;22(2):51-6. doi: 10.1023/a:1014416616687. J Clin Immunol. 2002. PMID: 11998892 Review.
Cited by
- Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink.
Hangasky JA, Waldmann TA, Santi DV. Hangasky JA, et al. Front Immunol. 2020 Aug 13;11:1813. doi: 10.3389/fimmu.2020.01813. eCollection 2020. Front Immunol. 2020. PMID: 32903632 Free PMC article. Review. - Practical NK cell phenotyping and variability in healthy adults.
Angelo LS, Banerjee PP, Monaco-Shawver L, Rosen JB, Makedonas G, Forbes LR, Mace EM, Orange JS. Angelo LS, et al. Immunol Res. 2015 Jul;62(3):341-56. doi: 10.1007/s12026-015-8664-y. Immunol Res. 2015. PMID: 26013798 Free PMC article. - Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Ando S, Kawada JI, Watanabe T, Suzuki M, Sato Y, Torii Y, Asai M, Goshima F, Murata T, Shimizu N, Ito Y, Kimura H. Ando S, et al. Oncotarget. 2016 Nov 22;7(47):76793-76805. doi: 10.18632/oncotarget.12529. Oncotarget. 2016. PMID: 27732937 Free PMC article. - Evaluation of the potency of the anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost study.
Mader A, Kunert R. Mader A, et al. PLoS One. 2012;7(6):e39063. doi: 10.1371/journal.pone.0039063. Epub 2012 Jun 15. PLoS One. 2012. PMID: 22720027 Free PMC article. - NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors.
Wang YA, Ranti D, Bieber C, Galsky M, Bhardwaj N, Sfakianos JP, Horowitz A. Wang YA, et al. Bladder Cancer. 2023 Jun 27;9(2):125-139. doi: 10.3233/BLC-220109. eCollection 2023. Bladder Cancer. 2023. PMID: 38993289 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials